Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17050471 | 0.84 | ACACB (0.55) | ACACBCSNK2A1KDM4E | |
| SCHEMBL17050816 | 0.80 | L3MBTL1 (0.42) | S1PR4L3MBTL1KDM4EOXTRHPGD | |
| SCHEMBL17050452 | 0.80 | MAPK8 (0.43) | SLC6A4ACACBS1PR4L3MBTL1KDM4E | |
| SCHEMBL17050451 | 0.79 | L3MBTL1 (0.41) | ACACBL3MBTL1KDM4EHPGD | |
| SCHEMBL17050453 | 0.77 | ACACB (0.53) | SLC6A4ACACBL3MBTL1KDM4EHPGD | |
| SCHEMBL17050467 | 0.76 | KDM4E (0.43) | L3MBTL1KDM4E | |
| SCHEMBL17050814 | 0.74 | ACACB (0.52) | ACACBL3MBTL1HPGD | |
| SCHEMBL17050815 | 0.73 | L3MBTL1 (0.48) | ACACBL3MBTL1MRGPRX4HPGD | |
| SCHEMBL17050822 | 0.73 | ACACB (0.42) | ACACBKDM4E | |
| SCHEMBL17050455 | 0.73 | ACACB (0.54) | SLC6A4ACACBS1PR4L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | SLC6A4 3519/4885ACACB 2/4885S1PR4 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.